Want to see IQV full AI Analyst Report?
IQV Stock Chart & Stats
$176.46
-$0.07(-0.03%)
At close: 4:00 PM EST
$176.46
-$0.07(-0.03%)
Day’s Range― - ―
52-Week Range$153.01 - $247.05
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.67M
Market Cap
$34.55B
Enterprise Value$42.60B
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$16.07B
Price to Earnings (P/E)25.4
Beta0.84
Next Earnings
Jul 28, 2026EPS Estimate
3.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.14
Shares Outstanding166,900,000
10 Day Avg. Volume1,611,498
30 Day Avg. Volume1,674,512
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda12.11
Forecast
1Y Price Target
$219.82Price Target Upside24.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)12.82
Revenue Forecast (FY)$17.29B
Bulls Say, Bears Say
Bulls Say
Durable Free Cash Flow GenerationIQVIA’s consistent operating cash flow and rebound in free cash flow provide a durable funding source for strategic priorities. Strong cash conversion supports continued buybacks, debt refinancing or paydown, and sustained investment in data and technology, reducing reliance on external capital over a multi-quarter horizon.
Large Backlog And Strong BookingsA $34.2B backlog and $2.5B of recent R&D bookings provide meaningful multi-quarter revenue visibility. With $8.9B anticipated to convert within 12 months, IQVIA can sustain near-term revenue and resource planning, lowering execution risk and supporting steady top-line momentum across its CRO and services businesses.
Strong AI/technology Adoption With Top ClientsRapid deployment of iqvia.ai and broad adoption by leading pharma clients strengthens IQVIA’s technology moat. Embedding analytics and AI into client workflows increases switching costs, supports recurring analytics and subscription revenue, and enhances cross-sell opportunities over the medium term as AI-enabled services scale.
Bears Say
Elevated Leverage And Debt LoadIQVIA’s elevated leverage reduces financial flexibility and increases sensitivity to interest-rate and refinancing risks. At ~3.6x net leverage, the company may face constrained optionality for large M&A or sustained buybacks if cash flow weakens, and higher interest costs could pressure free cash flow in adverse scenarios.
Margin Pressure From FX And MixManagement flagged a ~60bp EBITDA margin contraction driven by FX and lower pass-throughs, while TTM gross margins fell versus prior years. Persistent mix shifts or currency headwinds can erode operating leverage and cash conversion, limiting margin expansion even if top-line growth remains steady over the next several quarters.
Timing And Conversion Risk In BookingsLower-than-normal pass-throughs and a noted 12–18 month lag from funding to awards create timing risk: bookings may not translate to near-term revenue predictably. This mismatch can cause quarter-to-quarter revenue and cash flow volatility and reduces the reliability of bookings as a short-term growth signal.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest stock price was $153.01 and its highest was $247.04 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $34.55B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s upcoming earnings report date is Jul 28, 2026 which is in 22 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on May 05, 2026. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.816 by $0.084.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 3.04.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 166,900,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of $2.9 in its last earnings report, beating expectations of $2.816. Following the earnings report the stock price went up 9.618%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$219.82 (24.57% Upside)
$219.82 (24.57% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.74%
12-Months-Change
Fundamentals
Return on Equity
22.46%
Trailing 12-Months
Asset Growth
8.61%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad strength: record revenue, EPS beat, double-digit bookings growth in R&D Solutions, accelerating organic growth in both Commercial and R&D segments, strong free cash flow and share repurchases, meaningful customer wins and rapid AI adoption. Near-term caveats included unusually low pass-throughs that depressed a headline book-to-bill metric, a ~60 bps EBITDA margin contraction driven by FX and mix, and elevated net leverage (3.62x). Management reaffirmed revenue and EBITDA guidance and raised EPS guidance. On balance, the positives materially outweigh the negatives.View all IQV earnings summariesIQV Revenue Breakdown
40.63% Technology & Analytics Solutions
54.54% Research & Development Solutions
4.83% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$219.82
▲(24.57% Upside)
Technical Analysis
Ownership Overview
0.98% Insiders
27.83% Mutual Funds
0.08% Other Institutional Investors
44.06% Public Companies and
Individual Investors